Oral vs. Intravenous Hydration to Prevent Contrast-Associated Acute Kidney Injury in the ED
NCT07459413
Contrast-Associated Acute Kidney Injury, Contrast-induced Nephropathy
Istanbul, Gaziosmanpasa, Turkey (Türkiye)
View Trial DetailsNCT Number: NCT07813819
Iodinated contrast dye used during computed tomography (CT) scans can sometimes cause kidney stress or damage, known as contrast-associated acute kidney injury (CA-AKI). Currently, doctors evaluate a patient's kidney safety using standard estimated glomerular filtration rate (eGFR). However, standard eGFR is calculated for an average body size rather than an individual's actual body size, which can misrepresent a person's true kidney excretion capacity. This study aims to evaluate whether comparing the volume of contrast dye directly to a patient's true, individualized kidney function (the contrast volume-to-absolute GFR ratio) can accurately predict the risk of developing kidney injury after an intravenous contrast-enhanced CT scan.
This is a prospective, observational study involving adult outpatients who are already scheduled for a clinically necessary contrast-enhanced CT scan. Participation is observational and does not alter the patient's planned scan, medical treatment, or the amount of contrast dye administered by their healthcare team.
Participants will:
* Have their baseline kidney function assessed through a routine blood test (serum creatinine) within 48 hours prior to their CT scan. * Have their height and weight recorded to calculate their individualized, absolute kidney function. * Complete a follow-up blood test (serum creatinine) 48 to 72 hours after the CT scan to evaluate any changes in kidney function.
Researchers will analyze whether the ratio of contrast volume to absolute kidney function reliably identifies patients at higher risk of contrast-associated kidney complications, helping to establish safer, personalized contrast dosing strategies in the future.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
Contrast-associated acute kidney injury (CA-AKI) is defined according to Kidney Disease: Improving Global Outcomes (KDIGO) criteria as an absolute increase in serum creatinine of >= 0.3 mg/dL (>= 26.5 umol/L) within 48 hours, or a relative increase of >= 1.5 times the baseline value. Baseline serum creatinine is collected within 48 hours prior to contrast exposure, and follow-up serum creatinine is measured between 48 and 72 hours following intravenous contrast-enhanced CT.
Assiut University
Other
Prospective Evaluation of Contrast Volume as a Predictor of Contrast-Associated Acute Kidney Injury Following Intravenous Contrast-Enhanced Computed Tomography
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07459413
Contrast-Associated Acute Kidney Injury, Contrast-induced Nephropathy
Istanbul, Gaziosmanpasa, Turkey (Türkiye)
View Trial DetailsNCT07091656
Acute Kidney Injury, Contrast-Associated Acute Kidney Injury
Clichy, Île-de-France (Paris), France
View Trial DetailsNCT06596603
Contrast-Associated Acute Kidney Injury
Milan, Lombardy, Italy
View Trial DetailsNCT07546448
Acute Ischemic Stroke, Acute Kidney Injury
Diyarbakır, Outside of the US, Turkey (Türkiye)
View Trial Details